Mikhailidis D P, Barradas M A, Maris A, Jeremy J Y, Dandona P
J Clin Pathol. 1985 Oct;38(10):1166-71. doi: 10.1136/jcp.38.10.1166.
The effect of a human fibrinogen preparation on in vitro platelet aggregation was assessed. Platelets were obtained from healthy volunteers. Human fibrinogen induced platelet aggregation in 65% of platelet rich plasma samples and enhanced submaximal platelet aggregation induced by heparin or by several conventional agonists in all samples. Aggregation induced by fibrinogen alone was reversed by the in vitro addition of human albumin. Fibrinogen induced aggregation was associated with the release of the vasoconstrictor, thromboxane A2. Preincubation with indomethacin inhibited both the aggregation and the release of thromboxane A2. Fibrinogen had no effect on in vitro vascular prostaglandin I2 synthesis (rat aortic rings) during a 60 minute incubation. The observed effects of fibrinogen on platelet function may be relevant to clinical conditions in which hyperaggregability of platelets is associated with hyperfibrinogenemia and thrombosis.
评估了一种人纤维蛋白原制剂对体外血小板聚集的作用。血小板取自健康志愿者。人纤维蛋白原在65%的富含血小板血浆样本中诱导血小板聚集，并在所有样本中增强了由肝素或几种传统激动剂诱导的次最大血小板聚集。体外添加人白蛋白可逆转单独由纤维蛋白原诱导的聚集。纤维蛋白原诱导的聚集与血管收缩剂血栓素A2的释放有关。与吲哚美辛预孵育可抑制聚集和血栓素A2的释放。在60分钟的孵育过程中，纤维蛋白原对体外血管前列腺素I2合成（大鼠主动脉环）没有影响。观察到的纤维蛋白原对血小板功能的作用可能与血小板高聚集性与高纤维蛋白原血症和血栓形成相关的临床情况有关。
